3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Small Cell Lung Carcinoma
18
Lymphoma, Large B-Cell, Diffuse
16
Leukemia, Myeloid, Acute
16
Hodgkin Disease
16
Lymphoma
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Non-Hodgkin
12
Lung Neoplasms
12
Lymphoma, Mantle-Cell
10
Lymphoma, Follicular
10
Leukemia
10
Lymphoma, B-Cell
7
Carcinoma, Non-Small-Cell Lung
7
Burkitt Lymphoma
6
Recurrence
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Lymphoma, T-Cell
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, B-Cell, Marginal Zone
4
Congenital Abnormalities
4
Waldenstrom Macroglobulinemia
3
Plasmablastic Lymphoma
3
Ovarian Neoplasms
3
Lymphoma, Primary Effusion
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Erythroblastic, Acute
3
Immunoblastic Lymphadenopathy
3
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Metastatic Castration-Resistant Prostate Cancer
×
Etoposide
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled